France· FR:64854878
ADTRALZA 300 mg, solution injectable en stylo prérempli
A tralokinumab product, registered in France by LEO PHARMACEUTICAL PRODUCTS (DANEMARK), on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Tralokinumab is registered in 14 of 19 countries.
Countries holding a registration under ATC D11AH07 (tralokinumab), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 8 of them publish a price we can compare per daily dose
Tralokinumab · ATC D11AH07
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of tralokinumab costs, country by country.
Normalised to the WHO defined daily dose (16.1 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Tralokinumab · price per daily dose (16.1 mg)
USD · FX 28 Sept 2026
- CH Switzerland$34.49
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Manufacturer
- LEO PHARMACEUTICAL PRODUCTS (DANEMARK)
- Country
- France (FR)
- ATC code
- D11AH07
- ATC class
- Tralokinumab
- Defined daily dose
- 16.1 mg, P
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip1334009302761362 seringues préremplies en verre siliconé de 2 mL dans stylos pré-remplisEUR 743.64
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Tralokinumab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- IrelandAdtralza 300 mg solution for injection in pre-filled penLEO Pharma A/S
- NetherlandsAdtralza 300 mg, oplossing voor injectie in voorgevulde penLEO Pharma A/S
- CzechiaADTRALZALEO Pharma A/S, Ballerup
- CanadaADTRALZALEO PHARMA INC
- SwitzerlandAdtralza
- SpainADTRALZA 150 mg SOLUCION INYECTABLE EN JERINGA PRECARGADALeo Pharma A/S
- FinlandAdtralzaLeo Pharma A/S
- United StatesAdbryLEO Pharma Inc.
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Adtralza
- Iceland · Adtralza
- Liechtenstein · Adtralza
- Norway · Adtralza
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/4b94c5da-25db-48bd-9da5-c9f246783ac0 GET /v1/drugs/4b94c5da-25db-48bd-9da5-c9f246783ac0?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "64854878",
"date_amm": "2023-09-01",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/21/1554",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "solution injectable",
"voies_administration": "sous-cutanée",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about tralokinumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.